ALBERT PIERCE: Open Payments
NPI 1841850377 · TEMPE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 31 payments from 12 companies in 2025. Trend: 2023 $282 · 2024 $2,097 · 2025 $647
Food & beverage: $647
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $150 |
| Lundbeck LLC | 4 | $94 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Supernus Pharmaceuticals, Inc. | 3 | $71 |
| Alkermes, Inc. | 2 | $54 |
| ABBVIE INC. | 2 | $38 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Biogen, Inc. | 1 | $28 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
Products named: CAPLYTA, REXULTI, FANAPT, Qelbree, LYBALVI, VRAYLAR, COBENFY, TRINTELLIX.
Industry payments across AZ — which companies pay providers there.
